Cure My Disease

Don't miss your cure!

 Log in / Sign up

New TB drug cocktail aims to shorten treatment

NCT ID NCT06058299

Ongoing Disease control Sponsor: Global Alliance for TB Drug Development Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 trial tests whether a new drug called TBAJ-876, or the existing drug bedaquiline, combined with pretomanid and linezolid, can treat drug-sensitive tuberculosis faster and more effectively than the standard 6-month regimen. About 309 adults with newly diagnosed TB are taking part. The study compares how quickly the bacteria clear from sputum and checks safety over 26 weeks of treatment plus 52 weeks of follow-up.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
TBAJ-876 (also called sorfequiline), bedaquiline, pretomanid, linezolid, and standard TB drugs (isoniazid, rifampicin, pyrazinamide, ethambutol)
What this could lead to
If successful, this could lead to a shorter, simpler treatment regimen for drug-sensitive tuberculosis, potentially replacing the current standard of care.
What could go wrong
This is a Phase 2 trial with only 309 participants, so results may not apply to everyone. The new drug combinations may cause side effects like nerve damage or heart rhythm issues, and they might not work better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DRUG SENSITIVE TUBERCULOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pulmonary tuberculosis tuberculosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DRUG SENSITIVE TUBERCULOSIS PULMONARY TB PULMONARY TUBERCULOSIS

Contacts and locations

Locations

  • Care Clinical Trial Group Inc.

    Dasmariñas, 4114, Philippines

  • Case Western Reserve University- Research collaboration Uganda

    Kampala, Uganda

  • Desmond Tutu Health Foundation

    Cape Town, 7750, South Africa

  • Enhancing Care Foundation

    Durban, 4052, South Africa

  • Isango Lethemba TB Research Unit

    Port Elizabeth, 6200, South Africa

  • Joint Clinical Research Centre (JCRC)

    Kampala, Uganda

  • Kilimanjaro Christian Medical Centre

    Moshi, Tanzania

  • Lung Center of the Philippines

    Quezon City, 1104, Philippines

  • Madibeng Centre for Research

    Brits, 0250, South Africa

  • NIMR-MBEYA Medical Research Center

    Mbeya, Tanzania

  • National Center for Tuberculosis and Lung Diseases

    Tbilisi, 0101, Georgia

  • National Institute for Medical Research (NIMR)

    Mwanza, Tanzania

  • Perinatal HIV Research Unit (PHRU)

    Klerksdorp, 2571, South Africa

  • Setshaba Research Centre

    Soshanguve, Gauteng, 0152, South Africa

  • Synergy Biomed Research Institute (SBRI)

    East London, 5201, South Africa

  • TASK Brooklyn

    Cape Town, 7405, South Africa

  • TASK Eden

    George, 6529, South Africa

  • TB and HIV Investigative Network (THINK)

    Hillcrest, 3610, South Africa

  • The Aurum Institute

    Rustenburg, 2999, South Africa

  • Tropical Disease Foundation

    Makati City, 1230, Philippines

  • University of Cape Town Lung Institute (UCTLI)

    Cape Town, 7700, South Africa

  • WITS, Clinical HIV Research Unit (CHRU) Themba Lethu Clinic, Helen Joseph Hospital

    Johannesburg, 2092, South Africa

More trials for these conditions

Other studies related to the condition(s) this trial covers.